HeartWare pump thrombus concerns overblown, says Wells...

HeartWare pump thrombus concerns overblown, says Wells Fargo
Wells Fargo believes that concerns about the effects on HeartWare of a pump thrombus case involving one patient are overblown. The firm thinks the company reported good Q4 results, and it maintains an Outperform rating on the stock. :theflyonthewall.com


HeartWare price target raised to $88 from $77 at RW Baird
Baird raised its price target on Heartware following solid Q4 results citing strong revenue growth and earnings beat. The firm recommends sitting on the sidelines due to issues involving HVAD patients experiencing thrombosis and remains cautious until resolved. Shares remain Neutral rated. :theflyonthewall.com